Onco-Innovations Advances Manufacturing and Development of Novel PNKP Inhibitors for Hard-to-Treat Cancers

Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) is advancing a new class of DNA Damage Response (DDR) therapies through the development of Polynucleotide Kinase Phosphatase (PNKP) inhibitors, designed to disrupt cancer cells’ ability to repair DNA damage. The company recently achieved a key manufacturing milestone with the successful advancement toward kilogram-scale production of the active pharmaceutical ingredient in its lead drug candidate, ONC010.

A newly signed Letter of Intent with Nanosoft Polymers is expected to support polymer development, drug delivery optimization and formulation work for the ONC010 program. This collaboration aims to enhance the therapeutic potential of the PNKP inhibitor by improving its delivery to tumor sites.

Cancers frequently exhibit defective repair of damaged DNA, leading to the accumulation of mutations that can give rise to unchecked growth, evasion of the immune system, and the capacity to spread. Conventional DNA damaging therapies, like radiation treatment or some chemotherapies, can overwhelm a cancer’s limited repair capacity resulting in cancer cell death. However, some cancers retain sufficient DNA repair capacity to resist these treatments at doses patients can tolerate.

Onco-Innovations is positioning itself within this rapidly evolving area of oncology through the development of PNKP inhibitors. PNKP plays a critical role in repairing damaged DNA, and the company’s approach targets this enzyme to sensitize cancer cells to DNA-damaging agents, potentially overcoming resistance in hard-to-treat cancers. The advancement to kilogram-scale production of ONC010’s API is a significant step toward clinical trials and eventual commercialization.

The company’s focus on DDR therapies addresses a critical unmet need in oncology, as many cancers develop resistance to standard treatments. By inhibiting PNKP, Onco-Innovations aims to make cancer cells more vulnerable to existing therapies, offering a potential new option for patients with limited alternatives. The collaboration with Nanosoft Polymers underscores the importance of drug delivery in maximizing the efficacy of novel therapeutics.

For more information, visit the company’s newsroom at ibn.fm/ONNVF.

This press release is disseminated on behalf of Onco-Innovations Ltd. and may include paid advertising. BioMedWire (BMW) is a specialized communications platform focusing on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. For more information, visit https://www.BioMedWire.com.